BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 7198011)

  • 1. Cisplatin-induced emesis in the Ferret: a new animal model.
    Florczyk AP; Schurig JE; Bradner WT
    Cancer Treat Rep; 1982 Jan; 66(1):187-9. PubMed ID: 7198011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Olvanil: a non-pungent TRPV1 activator has anti-emetic properties in the ferret.
    Chu KM; Ngan MP; Wai MK; Yeung CK; Andrews PL; Percie du Sert N; Rudd JA
    Neuropharmacology; 2010 Feb; 58(2):383-91. PubMed ID: 19825380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-emetic activity of ghrelin in ferrets exposed to the cytotoxic anti-cancer agent cisplatin.
    Rudd JA; Ngan MP; Wai MK; King AG; Witherington J; Andrews PL; Sanger GJ
    Neurosci Lett; 2006 Jan; 392(1-2):79-83. PubMed ID: 16182445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of radiation-induced emesis in the ferret.
    King GL
    Radiat Res; 1988 Jun; 114(3):599-612. PubMed ID: 3375446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-HT3 receptor antagonists injected into the area postrema inhibit cisplatin-induced emesis in the ferret.
    Higgins GA; Kilpatrick GJ; Bunce KT; Jones BJ; Tyers MB
    Br J Pharmacol; 1989 May; 97(1):247-55. PubMed ID: 2720310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The delayed phase of cisplatin-induced emesis is mediated by the area postrema and not the abdominal visceral innervation in the ferret.
    Percie du Sert N; Rudd JA; Moss R; Andrews PL
    Neurosci Lett; 2009 Nov; 465(1):16-20. PubMed ID: 19733218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antagonism of cisplatin induced emesis in the dog.
    Gylys JA; Doran KM; Buyniski JP
    Res Commun Chem Pathol Pharmacol; 1979 Jan; 23(1):61-8. PubMed ID: 441517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5-Hydroxytryptamine M-receptor antagonism to prevent cisplatin-induced emesis.
    Costall B; Domeney AM; Naylor RJ; Tattersall FD
    Neuropharmacology; 1986 Aug; 25(8):959-61. PubMed ID: 3774121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of three preclinical models for nausea and vomiting assessment.
    Goineau S; Castagné V
    J Pharmacol Toxicol Methods; 2016; 82():45-53. PubMed ID: 27477617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Action of (R)-sila-venlafaxine and reboxetine to antagonize cisplatin-induced acute and delayed emesis in the ferret.
    Warneck JB; Cheng FH; Barnes MJ; Mills JS; Montana JG; Naylor RJ; Ngan MP; Wai MK; Daiss JO; Tacke R; Rudd JA
    Toxicol Appl Pharmacol; 2008 Nov; 232(3):369-75. PubMed ID: 18675289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiemetic activity of butorphanol against cisplatin-induced emesis in ferrets and dogs.
    Schurig JE; Florczyk AP; Rose WC; Bradner WT
    Cancer Treat Rep; 1982 Oct; 66(10):1831-5. PubMed ID: 6889914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emesis, radiation exposure, and local cerebral blood flow in the ferret.
    Tuor UI; Kondysar MH; Harding RK
    Radiat Res; 1988 Jun; 114(3):537-49. PubMed ID: 3375441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Action of ondansetron and CP-99,994 to modify behavior and antagonize cisplatin-induced emesis in the ferret.
    Lau AH; Kan KK; Lai HW; Ngan MP; Rudd JA; Wai MK; Yew DT
    Eur J Pharmacol; 2005 Jan; 506(3):241-7. PubMed ID: 15627434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using telemetry to automate the detection of emesis in the ferret: new vistas for delayed emesis assessment.
    Goineau S; Rompion S; Guillaume P; Barrais L; Castagné V
    J Pharmacol Toxicol Methods; 2013; 68(1):160-5. PubMed ID: 23578691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emesis induced by cisplatin in the ferret as a model for the detection of anti-emetic drugs.
    Costall B; Domeney AM; Naylor RJ; Tattersall FD
    Neuropharmacology; 1987 Sep; 26(9):1321-6. PubMed ID: 2890117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BMY-25801, an antiemetic agent free of D2-dopamine receptor antagonist properties.
    Gylys JA; Wright RN; Nicolosi WD; Buyniski JP; Crenshaw RR
    J Pharmacol Exp Ther; 1988 Mar; 244(3):830-7. PubMed ID: 2978041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of the abdominal visceral innervation and 5-hydroxytryptamine M-receptors in vomiting induced by the cytotoxic drugs cyclophosphamide and cis-platin in the ferret.
    Hawthorn J; Ostler KJ; Andrews PL
    Q J Exp Physiol; 1988 Jan; 73(1):7-21. PubMed ID: 3347698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of cisplatin-induced delayed emesis: still unsatisfactory. Italian Group for Antiemetic Research.
    Support Care Cancer; 2000 May; 8(3):229-32. PubMed ID: 10789965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Olvanil, a non-pungent vanilloid enhances the gastrointestinal toxicity of cisplatin in the ferret.
    Chu KM; Ngan MP; Wai MK; Yeung CK; Andrews PL; Percie du Sert N; Lin G; Rudd JA
    Toxicol Lett; 2010 Feb; 192(3):402-7. PubMed ID: 19931602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Profiles of emetic action of cisplatin in the ferret: a potential model of acute and delayed emesis.
    Rudd JA; Jordan CC; Naylor RJ
    Eur J Pharmacol; 1994 Sep; 262(1-2):R1-2. PubMed ID: 7813558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.